PL445254A1 - Polipeptyd i jego zastosowanie jako środek bakteriobójczy wobec bakterii Rothia sp. - Google Patents

Polipeptyd i jego zastosowanie jako środek bakteriobójczy wobec bakterii Rothia sp.

Info

Publication number
PL445254A1
PL445254A1 PL445254A PL44525423A PL445254A1 PL 445254 A1 PL445254 A1 PL 445254A1 PL 445254 A PL445254 A PL 445254A PL 44525423 A PL44525423 A PL 44525423A PL 445254 A1 PL445254 A1 PL 445254A1
Authority
PL
Poland
Prior art keywords
polypeptide
rothia
bactericidal agent
agent against
pneumonia
Prior art date
Application number
PL445254A
Other languages
English (en)
Other versions
PL248944B1 (pl
Inventor
Paulina Miernikiewicz
Krystyna DĄBROWSKA
Aleksandra Wilczak
Jakub Barylski
Sophia Bałdysz
Original Assignee
Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan We Wrocławiu
Uniwersytet Im. Adama Mickiewicza W Poznaniu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan We Wrocławiu, Uniwersytet Im. Adama Mickiewicza W Poznaniu filed Critical Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan We Wrocławiu
Priority to PL445254A priority Critical patent/PL248944B1/pl
Publication of PL445254A1 publication Critical patent/PL445254A1/pl
Publication of PL248944B1 publication Critical patent/PL248944B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01092—Peptidoglycan beta-N-acetylmuramidase (3.2.1.92)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem zgłoszenia jest polipeptyd o właściwościach bakteriobójczych, specyficzny wobec szczepów bakterii Rothia sp. Przedmiotem zgłoszenia jest również kompozycja farmaceutyczna zawierająca rzeczony polipeptyd, a także zastosowanie wspomnianego polipeptydu do zapobiegania i leczenia chorób wywołanych zakażeniem szczepami bakterii Rothia sp. takich jak zapalenie wsierdzia, zapalenie płuc, zapalenie otrzewnej, sepsa, zapalenie opon mózgowych, zapalenie płuc, mukowiscydoza lub infekcje związane z protezami.
PL445254A 2023-06-17 2023-06-17 Polipeptyd i jego zastosowanie jako środek bakteriobójczy wobec bakterii Rothia sp. PL248944B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL445254A PL248944B1 (pl) 2023-06-17 2023-06-17 Polipeptyd i jego zastosowanie jako środek bakteriobójczy wobec bakterii Rothia sp.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445254A PL248944B1 (pl) 2023-06-17 2023-06-17 Polipeptyd i jego zastosowanie jako środek bakteriobójczy wobec bakterii Rothia sp.

Publications (2)

Publication Number Publication Date
PL445254A1 true PL445254A1 (pl) 2024-12-23
PL248944B1 PL248944B1 (pl) 2026-02-16

Family

ID=94644287

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445254A PL248944B1 (pl) 2023-06-17 2023-06-17 Polipeptyd i jego zastosowanie jako środek bakteriobójczy wobec bakterii Rothia sp.

Country Status (1)

Country Link
PL (1) PL248944B1 (pl)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018854A2 (en) * 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
WO2008108877A2 (en) * 2006-08-29 2008-09-12 The United States Of America, As Represented By The Secretary Of Agriculture Specific lysis of staphylococcal pathogens by bacteriophage phi1 1 endolysin
US20100172918A1 (en) * 2009-01-08 2010-07-08 Intron Biotechnology, Inc. Novel lysin protein having broad antibacterial activity specific to bacteria
WO2013052643A1 (en) * 2011-10-05 2013-04-11 The Rockefeller University Dimeric bacteriophage lysins
WO2014039436A1 (en) * 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary Of Agriculture Staphylococcus haemolyticus prophage φsh2 endolysin is lytic for staphylococcus aureus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008018854A2 (en) * 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
WO2008108877A2 (en) * 2006-08-29 2008-09-12 The United States Of America, As Represented By The Secretary Of Agriculture Specific lysis of staphylococcal pathogens by bacteriophage phi1 1 endolysin
US20100172918A1 (en) * 2009-01-08 2010-07-08 Intron Biotechnology, Inc. Novel lysin protein having broad antibacterial activity specific to bacteria
WO2013052643A1 (en) * 2011-10-05 2013-04-11 The Rockefeller University Dimeric bacteriophage lysins
WO2014039436A1 (en) * 2012-09-06 2014-03-13 The United States Of America, As Represented By The Secretary Of Agriculture Staphylococcus haemolyticus prophage φsh2 endolysin is lytic for staphylococcus aureus

Also Published As

Publication number Publication date
PL248944B1 (pl) 2026-02-16

Similar Documents

Publication Publication Date Title
Gottardi et al. N-chloramines, a promising class of well-tolerated topical anti-infectives
Hoyle et al. Bacterial resistance to antibiotics: the role of biofilms
JOP20250072A1 (ar) المركبات ثلاثية الحلقات واستخداماتها
Michon et al. Advances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patients
AU2019271937A1 (en) Compositions and method for destabilizing, altering, and dispersing biofilms
EP0665754A4 (en) ANTIMICROBIAL POLYPEPTIDES.
MX2022011291A (es) Nueva lisina recombinante y su uso en el tratamiento de infecciones por bacterias gramnegativas.
CN115837068B (zh) 枯草菌脂肽钠的用途、组合物及其使用方法
Aybar et al. Efficacy of tigecycline and vancomycin in experimental catheter-related Staphylococcus epidermidis infection: microbiological and electron microscopic analysis of biofilm
Daffinee et al. Eradication of Staphylococcus epidermidis within biofilms: comparison of systemic versus supratherapeutic concentrations of antibiotics
ZA202405840B (en) A hygiene composition
Celandroni et al. Antimicrobial activity of Xibornol and a Xibornol-based formulation against gram-positive pathogens of the respiratory tract
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
CL2022000990A1 (es) Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1
ZA202210318B (en) Use of a thienopyridone derivative in the treatment of autosomal dominant polycystic kidney disease (adpkd)
EP4344749A3 (en) Protease formulation for treatment of microbial infections
Salih et al. Staphylococcus epidermidis isolates from nares and prosthetic joint infections are mupirocin susceptible
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
MX2021010552A (es) Nuevo peptido y uso del mismo.
Warrier et al. Susceptibility of Minocycline against Carbapenem resistant gram-negative bacilli
Khalaf et al. Antibiofilm activity of klebocin crude extract against some species of Enterobacteriaceae
AR123060A1 (es) Formulaciones
AR123551A1 (es) Formas farmacéuticas sólidas de bacterias
Rathinam et al. Biosurfactant as an intervention for medical device associated infections
Rosin et al. Bacteriological assistance for optimal antibiotic therapy of endocarditis